Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs TESTOSTERONE CYPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Off-label: Treatment of chronic pain when other options fail
Male hypogonadism (primary or hypogonadotropic),Delayed puberty in males,Off-label: Female-to-male gender affirmation therapy, anemia of renal failure (historically)
One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
Oxycodone: 3-5 hours; Ibuprofen: 1.8-2.5 hours. Clinical context: Oxycodone's half-life allows dosing every 4-6 hours; Ibuprofen's shorter half-life supports frequent dosing for sustained anti-inflammatory effect.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Oxycodone is metabolized primarily via CYP3A4 and CYP2D6 to active metabolites (noroxycodone, oxymorphone). Ibuprofen is metabolized via CYP2C9 and CYP2C8 to inactive metabolites.
Primarily hepatic via CYP3A4 and CYP2B6; metabolites include androsterone and etiocholanolone; excreted in urine.
Oxycodone: primarily renal (87%) as metabolites, with ~19% unchanged; Ibuprofen: renal (90%) as metabolites, with ~10% unchanged; small biliary/fecal elimination for both.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Oxycodone: ~45% bound to albumin; Ibuprofen: >99% bound to albumin.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin
Oxycodone: Vd 2.0-3.0 L/kg (high tissue distribution: CNS, muscle); Ibuprofen: Vd 0.1-0.2 L/kg (limited to plasma and extracellular fluid).
Approximately 0.6-1.0 L/kg (reflects extensive distribution into tissues, including muscle and fat; total Vd ~4-9 L in adults)
Oral: Oxycodone 60-87% (higher with repeated dosing due to saturation of first-pass); Ibuprofen 80-100% (rapidly absorbed).
Intramuscular: 100% (administered as a depot injection in oil; undergoes first-pass metabolism if oral, but not relevant for IM route)
GFR 30-89 m L/min: No adjustment recommended. GFR 15-29 m L/min: Use with caution; consider reducing dose or extending interval; avoid use in severe renal impairment (GFR <30 m L/min) due to risk of ibuprofen accumulation and nephrotoxicity. GFR <15 m L/min: Not recommended.
No specific dose adjustment recommended; however, monitor fluid retention and hypertension in patients with severe renal impairment (GFR <30 m L/min).
Child-Pugh Class A (mild): No adjustment recommended. Child-Pugh Class B (moderate): Use with caution; reduce starting dose of oxycodone by 50% (e.g., half tablet) and monitor; ibuprofen should be avoided or used at lowest effective dose. Child-Pugh Class C (severe): Contraindicated due to risk of hepatic encephalopathy and bleeding.
Child-Pugh A/B: No adjustment; Child-Pugh C: Contraindicated due to risk of hepatotoxicity.
Not approved in children <18 years of age. For weight-based dosing in adolescents (≥18 years): same as adult based on oxycodone component 0.05-0.15 mg/kg/dose (max 5 mg) and ibuprofen 5-10 mg/kg/dose (max 400 mg) every 6 hours as needed; not to exceed 4 doses per day.
Not recommended for use in pediatric patients for hypogonadism; for delayed puberty, IM testosterone cypionate 50 mg every 4 weeks initially, titrating upward as needed.
Start at lowest effective dose (one-half tablet every 6 hours) due to increased sensitivity to opioids (respiratory depression, constipation) and NSAID-related GI/renal risks; monitor renal function and for cognitive impairment; maximum 4 tablets per day.
Start at lower end of dosing range (e.g., 50-100 mg every 2-4 weeks) due to increased risk of prostate enlargement and cardiovascular events; monitor serum testosterone levels and adjust accordingly.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of just one dose, especially by children, can be fatal; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to ibuprofen.
Prolonged use of high doses of testosterone has been associated with an increased risk of hepatocellular carcinoma.
Respiratory depression; addiction potential; interactions with CNS depressants; hepatic impairment; renal toxicity; gastrointestinal bleeding; cardiovascular thrombotic events; adrenal insufficiency; use in elderly; use in pregnancy; breastfeeding.
Risk of polycythemia (monitor hematocrit), edema in patients with cardiac/renal/hepatic disease, accelerated growth in prepubertal males (monitor bone age), gynecomastia, sleep apnea exacerbation, prostate hyperplasia/carcinoma (monitor PSA), decreased spermatogenesis, elevated blood pressure, hyperlipidemia.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; hypersensitivity to oxycodone, ibuprofen, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of coronary artery bypass graft (CABG) surgery.
Known or suspected prostate carcinoma, male breast carcinoma, pregnancy, hypersensitivity to testosterone cypionate, severe hepatic/renal/cardiac disease (relative), hypercalcemia (in patients with immobility).
Take with food or milk to reduce GI upset. Avoid grapefruit and grapefruit juice (may increase oxycodone levels and risk of adverse effects). Limit alcohol intake due to additive CNS depression and increased GI bleeding risk.
No significant food interactions. Limit alcohol consumption as it may increase risk of liver damage. Grapefruit juice may interfere with testosterone metabolism; avoid excessive intake.
First trimester: Limited data; opioid use associated with neural tube defects and congenital heart defects in some studies; ibuprofen associated with increased risk of cardiac defects and gastroschisis. Second trimester: Ibuprofen may cause oligohydramnios and premature closure of fetal ductus arteriosus. Third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome; ibuprofen contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal nephrotoxicity.
Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and third trimester exposure can also cause virilization. No adequate studies exist; use only if clearly needed for maternal condition, though use in pregnancy is generally avoided.
Oxycodone excreted in breast milk; M/P ratio approximately 1.1. Ibuprofen excreted in low levels (M/P <0.01). American Academy of Pediatrics considers both compatible with breastfeeding; however, monitor infant for sedation, respiratory depression, and poor feeding due to oxycodone.
Testosterone is excreted into breast milk in low concentrations; M/P ratio not reported. Theoretical risk of androgenic effects in male infants (e.g., masculinization). Use with caution only if maternal benefit outweighs potential risk. Consider alternative therapies while breastfeeding.
No established dose adjustments for pregnancy; however, increased renal clearance and volume of distribution in pregnancy may require dose increases for adequate analgesia. Avoid supratherapeutic ibuprofen doses; limit to lowest effective dose and shortest duration. Third trimester: avoid ibuprofen entirely.
No specific dose adjustment studies exist. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) may reduce efficacy, but use of testosterone cypionate during pregnancy is contraindicated. If essential, dose may need titration to maintain desired androgen levels; however, risk outweighs benefit.
Combination product (oxycodone 5 mg/ibuprofen 400 mg) indicated for acute moderate-to-severe pain; limit duration to ≤7 days due to opioid dependence and GI/renal risks; avoid in patients with aspirin/NSAID allergy, asthma, or severe hepatic/renal impairment; monitor for respiratory depression, hypotension, and signs of bleeding; prescribe naloxone for high-risk patients.
Testosterone cypionate is a long-acting injectable androgen. Monitor hematocrit and hemoglobin due to risk of polycythemia. Use with caution in patients with sleep apnea, benign prostatic hyperplasia, or cardiovascular disease. Check serum testosterone levels 1 week after injection to assess adequacy. For men with hypogonadism, avoid in those with untreated hyperprolactinemia or pituitary tumor.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not drive or operate machinery until you know how this medication affects you.,This drug contains both an opioid and an NSAID; risk of addiction, respiratory depression, and GI bleeding.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or acetaminophen-containing products without medical advice.,Swallow tablets whole; do not crush, chew, or dissolve (may cause rapid release and overdose).,Common side effects: constipation, nausea, dizziness, drowsiness; increase fluids and fiber to prevent constipation.,Seek emergency help if you experience trouble breathing, chest pain, severe dizziness, black/tarry stools, or signs of allergic reaction.,Keep out of reach of children and dispose of unused medication via drug take-back program.,Inform all healthcare providers that you are taking this medication before any surgery or procedure.
Inject deeply into the muscle (gluteal or thigh) to reduce pain and risk of abscess.,Do not use if you have breast cancer, prostate cancer, or are pregnant.,Report swelling in ankles, difficulty breathing, or severe headache immediately.,Do not take with blood thinners like warfarin without consulting your doctor.,Expect possible mood changes, increased acne, or hair loss. Monitor for priapism.,Regular blood tests are required to check red blood cell count, liver function, and prostate health.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Chlorpropamide, a sulfonylurea antidiabetic agent, stimulates pancreatic insulin secretion, while testosterone may enhance insulin sensitivity and reduce blood glucose levels. Concurrent use can lead to additive hypoglycemic effects, increasing the risk of hypoglycemia, particularly in patients with diabetes. This interaction is of clinical concern as it may necessitate dose adjustments of chlorpropamide to prevent hypoglycemic episodes."
"Flunisolide, a corticosteroid with mineralocorticoid activity, can potentiate the sodium- and water-retaining effects of testosterone, leading to an increased risk of edema, hypertension, and exacerbation of heart failure. This interaction is particularly significant in patients with pre-existing cardiovascular conditions, as the combined effects on fluid balance may require dose adjustments or closer monitoring."
"Fluorometholone, a corticosteroid with mineralocorticoid activity, may enhance sodium and water retention induced by testosterone, particularly in patients with pre-existing cardiac or renal conditions. This interaction can lead to increased fluid retention, exacerbation of hypertension, and potential precipitation of congestive heart failure. The risk is greater with high doses or prolonged use of either agent."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE HYDROCHLORIDE AND IBUPROFEN vs TESTOSTERONE CYPIONATE, answered by our medical review team.
OXYCODONE HYDROCHLORIDE AND IBUPROFEN is a Opioid Agonist that works by Oxycodone is a full mu-opioid receptor agonist, leading to analgesia, euphoria, and sedation. Ibuprofen inhibits cyclooxygenase (COX)-1 and COX-2, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.. TESTOSTERONE CYPIONATE is a Androgen that works by Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE HYDROCHLORIDE AND IBUPROFEN and TESTOSTERONE CYPIONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE HYDROCHLORIDE AND IBUPROFEN is: One tablet containing oxycodone hydrochloride 5 mg and ibuprofen 400 mg orally every 6 hours as needed for pain; maximum 4 tablets per day.. The standard adult dose of TESTOSTERONE CYPIONATE is: Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE HYDROCHLORIDE AND IBUPROFEN and TESTOSTERONE CYPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE HYDROCHLORIDE AND IBUPROFEN is classified as Category D/X. First trimester: Limited data; opioid use associated with neural tube defects and congenital heart defects in some studies; ibuprofen associated with increased risk of cardiac defe. TESTOSTERONE CYPIONATE is classified as Category D/X. Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.